Global Anti-TIGIT Antibody Market Segment Research Report 2024
Summary
The global and Chinese economies were hit hard in 2020, and the global GDP grew by 5.9% in 2021. Although the global growth prospects improved and there was a V-shaped rebound, this does not mean that the economy has really recovered to the level before the epidemic. The vast majority of countries are still in the stage of recovery after heavy damage and are far from achieving real recovery.
2022 is a year of continuous recovery. Global supply chain disturbance, geopolitical tension, energy price fluctuation, local labor shortage and rising raw material prices will affect the resilience of economic recovery. The International Monetary Fund (IMF) predicts that the world economy will grow by 4.4% in 2022, of which the U.S. economy will grow by about 4%. Driven by China and India, Asia is expected to become the fastest growing region in the world in 2022. However, China's economic growth has slowed down. The 2022 government work report shows that the expected target of economic growth is set at about 5.5%.
According to research, China has set a growth rate of about 5.5%, which not only focuses on the speed of economic growth, but also anchors the quality of economic development. Scientific and technological innovation, economic and social digitization and green development will be the long-term goals of China's economic development. It is expected that in 2022, major economies such as the United States, Europe and China will introduce more favorable policies to drive the development of switching power supply industry.
Beijing Yanjing Bizhi Information Consulting Co., Ltd. (XYZResearch)released the 《(Post-pandemic Era)-Global Anti-TIGIT Antibody Market Segment Research Report 2022》, which aims to sort out the development status and trends of the Anti-TIGIT Antibody industry at home and abroad, estimate the overall market scale of the Anti-TIGIT Antibody industry and the market share of major countries, Anti-TIGIT Antibody industry, and study and judge the downstream market demand of Anti-TIGIT Antibody through systematic research, Analyze the competition pattern of Anti-TIGIT Antibody, so as to help solve the pain points of various stakeholders in Anti-TIGIT Antibody industry. This industry research report combines desktop research, qualitative interviews with insiders or experts and other methods to strive for the objectivity and integrity of conclusions and data.
Regional Segmentation (Value; Revenue, USD Million, 2018-2028) of Anti-TIGIT Antibody Market by XYZResearch Include
USA
Europe
China
Japan
India
Korea
Southeast Asia
Competitive Analysis; Who are the Major Players in Anti-TIGIT Antibody Market?
Roche
Merck
AstraZeneca
Arcus
Astellas
BeiGene
BMS
Junshi Biosciences
Innovent Biologics
Mereo BioPharma
Seattle Genetics
Hengrui Medicine
Compugen
Major Type of Anti-TIGIT Antibody Covered in XYZResearch report
Monotherapy
Combination Therapy
Application Segments Covered in XYZResearch Market
Cell Carcinoma
Solid Tumor
For any other requirements, please feel free to contact us and we will provide you customized report.
Table of Content
Table of Contents
Global Anti-TIGIT Antibody Market Segment Research Report 2022
1. Research Scope
2. Market Overview
2.1 Product Introduction, Application, Picture
2.2 Global Anti-TIGIT Antibody Market by Value
2.2.1 Global Anti-TIGIT Antibody Revenue by Type
2.2.2 Global Anti-TIGIT Antibody Market by Value (%)
2.3 Global Anti-TIGIT Antibody Market by Production
2.3.1 Global Anti-TIGIT Antibody Production by Type
2.3.2 Global Anti-TIGIT Antibody Market by Production (%)
3. The Major Driver of Anti-TIGIT Antibody Industry
3.1 Historical & Forecast Global Anti-TIGIT Antibody Demand
3.2 Largest Application for Anti-TIGIT Antibody (2018-2028)
3.3 The Major Downstream Company in China Market 2022
4. Global and Regional Anti-TIGIT Antibody Market
4.1 Regional Market Size in Terms of Production & Demand (2022)
4.2 Regional Market Share in Terms of Revenue (2018-2022)
4.3 Concentration Ratio (CR5& CR10) of Anti-TIGIT Antibody Market
4.4 Mergers & Acquisitions, Expansion Plans
5. US Anti-TIGIT Antibody Production, Revenue (2018-2028)
5.1 Current and Estimated Production Breakdown by Type
5.2 Current and Estimated Production Breakdown by Application
5.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
5.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
6. Europe Anti-TIGIT Antibody Production, Revenue (2018-2028)
6.1 Current and Estimated Production Breakdown by Type
6.2 Current and Estimated Production Breakdown by Application
6.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
6.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
7. China Anti-TIGIT Antibody Production, Revenue (2018-2028)
7.1 Current and Estimated Production Breakdown by Type
7.2 Current and Estimated Production Breakdown by Application
7.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
7.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
8. Japan Anti-TIGIT Antibody Production, Revenue (2018-2028)
8.1 Current and Estimated Production Breakdown by Type
8.2 Current and Estimated Production Breakdown by Application
8.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
8.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
9. India Anti-TIGIT Antibody Production, Revenue (2018-2028)
9.1 Current and Estimated Production Breakdown by Type
9.2 Current and Estimated Production Breakdown by Application
9.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
9.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
10. Korea Anti-TIGIT Antibody Production, Revenue (2018-2028)
10.1 Current and Estimated Production Breakdown by Type
10.2 Current and Estimated Production Breakdown by Application
10.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
10.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
11. Southeast Asia Anti-TIGIT Antibody Production, Revenue (2018-2028)
11.1 Current and Estimated Production Breakdown by Type
11.2 Current and Estimated Production Breakdown by Application
11.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
11.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
12. Global Anti-TIGIT Antibody Average Price Trend
12.1 Market Price for Each Type of Anti-TIGIT Antibody in US (2018-2022)
12.2 Market Price for Each Type of Anti-TIGIT Antibody in Europe (2018-2022)
12.3 Market Price for Each Type of Anti-TIGIT Antibody in China (2018-2022)
12.4 Market Price for Each Type of Anti-TIGIT Antibody in Japan (2018-2022)
12.5 Market Price for Each Type of Anti-TIGIT Antibody in India (2018-2022)
12.6 Market Price for Each Type of Anti-TIGIT Antibody in Korea (2018-2022)
12.7 Market Price for Each Type of Anti-TIGIT Antibody in Southeast Asia (2018-2022)
13. Industrial Chain (Impact of COVID-19)
13.1 Anti-TIGIT Antibody Industrial Chain Analysis
13.2 Downstream
13.3 Impact of COVID-19
13.4 Post-pandemic Era
13.5 Technology Trends of Anti-TIGIT Antibody
14. Anti-TIGIT Antibody Competitive Landscape
14.1 Roche
14.1.1 Roche Company Profiles
14.1.2 Roche Product Introduction
14.1.3 Roche Anti-TIGIT Antibody Production, Revenue (2018-2022)
14.1.4 Strategic initiatives
14.2 Merck
14.2.1 Merck Company Profiles
14.2.2 Merck Product Introduction
14.2.3 Merck Anti-TIGIT Antibody Production, Revenue (2018-2022)
14.2.4 Strategic initiatives
14.3 AstraZeneca
14.3.1 AstraZeneca Company Profiles
14.3.2 AstraZeneca Product Introduction
14.3.3 AstraZeneca Anti-TIGIT Antibody Production, Revenue (2018-2022)
14.3.4 Strategic initiatives
14.4 Arcus
14.4.1 Arcus Company Profiles
14.4.2 Arcus Product Introduction
14.4.3 Arcus Anti-TIGIT Antibody Production, Revenue (2018-2022)
14.4.4 Strategic initiatives
14.5 Astellas
14.5.1 Astellas Company Profiles
14.5.2 Astellas Product Introduction
14.5.3 Astellas Anti-TIGIT Antibody Production, Revenue (2018-2022)
14.5.4 Strategic initiatives
14.6 BeiGene
14.6.1 BeiGene Company Profiles
14.6.2 BeiGene Product Introduction
14.6.3 BeiGene Anti-TIGIT Antibody Production, Revenue (2018-2022)
14.6.4 Strategic initiatives
14.7 BMS
14.7.1 BMS Company Profiles
14.7.2 BMS Product Introduction
14.7.3 BMS Anti-TIGIT Antibody Production, Revenue (2018-2022)
14.7.4 Strategic initiatives
14.8 Junshi Biosciences
14.8.1 Junshi Biosciences Company Profiles
14.8.2 Junshi Biosciences Product Introduction
14.8.3 Junshi Biosciences Anti-TIGIT Antibody Production, Revenue (2018-2022)
14.8.4 Strategic initiatives
14.9 Innovent Biologics
14.9.1 Innovent Biologics Company Profiles
14.9.2 Innovent Biologics Product Introduction
14.9.3 Innovent Biologics Anti-TIGIT Antibody Production, Revenue (2018-2022)
14.9.4 Strategic initiatives
14.10 Mereo BioPharma
14.10.1 Mereo BioPharma Company Profiles
14.10.2 Mereo BioPharma Product Introduction
14.10.3 Mereo BioPharma Anti-TIGIT Antibody Production, Revenue (2018-2022)
14.10.4 Strategic initiatives
14.11 Seattle Genetics
14.12 Hengrui Medicine
14.13 Compugen
15. Conclusion
16. Methodology and Data Source
List of Figure
List of Tables and Figures
Figure 1. Total Demand by Application of Anti-TIGIT Antibody Industry (Volume)
Figure 2. Anti-TIGIT Antibody Production & Demand by Regions in 2022
Figure 3. Regional Market Share in Terms of Revenue (2022&2027)
Figure 4. The Top 10 and 5 Players Market Share by Anti-TIGIT Antibody Revenue in 2022
Figure 5. US Anti-TIGIT Antibody Production, Demand (2018-2028)
Figure 6. Production Breakdown by Type (%)
Figure 7. Demand Breakdown by Type (%)
Figure 8. Demand Breakdown by Application (%)
Figure 9. Revenue Breakdown by Type (%)
Figure 10. Revenue Breakdown by Application (%)
Figure 11. Europe Anti-TIGIT Antibody Production, Demand (2018-2028)
Figure 12. Production Breakdown by Type (%)
Figure 13. Demand Breakdown by Type (%)
Figure 14. Demand Breakdown by Application (%)
Figure 15. Revenue Breakdown by Type (%)
Figure 16. Revenue Breakdown by Application (%)
Figure 17. China Anti-TIGIT Antibody Production, Demand (2018-2028)
Figure 18. Production Breakdown by Type (%)
Figure 19. Demand Breakdown by Type (%)
Figure 20. Demand Breakdown by Application (%)
Figure 21. Current and Estimated Revenue Breakdown by Type
Figure 22. Revenue Breakdown by Type (%)
Figure 23. Revenue Breakdown by Application (%)
Figure 24. Japan Anti-TIGIT Antibody Production, Demand (2018-2028)
Figure 25. Production Breakdown by Type (%)
Figure 26. Demand Breakdown by Type (%)
Figure 27. Demand Breakdown by Application (%)
Figure 28. Revenue Breakdown by Type (%)
Figure 29. Revenue Breakdown by Application (%)
Figure 30. India Anti-TIGIT Antibody Production, Demand (2018-2028)
Figure 31. Production Breakdown by Type (%)
Figure 32. Demand Breakdown by Type (%)
Figure 33. Demand Breakdown by Application (%)
Figure 34. Revenue Breakdown by Type (%)
Figure 35. Revenue Breakdown by Application (%)
Figure 36. Korea Anti-TIGIT Antibody Production, Demand (2018-2028)
Figure 37. Production Breakdown by Type (%)
Figure 38. Demand Breakdown by Type (%)
Figure 39. Demand Breakdown by Application (%)
Figure 40. Revenue Breakdown by Type (%)
Figure 41. Revenue Breakdown by Application (%)
Figure 42. Southeast Asia Anti-TIGIT Antibody Production, Demand (2018-2028)
Figure 43. Current and Estimated Production Breakdown by Type (2018-2028)
Figure 44. Production Breakdown by Type (%)
Figure 45. Demand Breakdown by Type (%)
Figure 46. Revenue Breakdown by Type (%)
Figure 47. Revenue Breakdown by Application (%)
Figure 48. Industrial Chain
Table 1. Top Manufacturers and Market Segmentation
Table 2. Product Introduction, Application, Picture
Table 3. Anti-TIGIT Antibody Revenue, by Type (Million USD) (2018-2028)
Table 4. Anti-TIGIT Antibody Production, by Type (K Unit) (2018-2028)
Table 5. Anti-TIGIT Antibody Demand (K Unit) by Application (2018-2028)
Table 6. Anti-TIGIT Antibody Demand (Million USD) by Application (2018-2028)
Table 7. The Major Downstream Company in China
Table 8. Regional Market Share in Terms of Production & Demand (2022)
Table 9. Regional Market Share in Terms of Revenue (2022&2027)
Table 10. Ranking of Global Top Anti-TIGIT Antibody Companies by Revenue, Concentration Ratio in 2022
Table 11. Mergers & Acquisitions, Expansion Plans
Table 12. US Anti-TIGIT Antibody Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 13. Current and Estimated Production Breakdown by Type (2018-2028)
Table 14. Current and Estimated Demand Breakdown by Type (2018-2028)
Table 15. Current and Estimated Demand Breakdown by Application (2018-2028)
Table 16. Current and Estimated Revenue Breakdown by Type
Table 17. Current and Estimated Revenue Breakdown by Application
Table 18. Europe Anti-TIGIT Antibody Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 19. Current and Estimated Production Breakdown by Type (2018-2028)
Table 20. Current and Estimated Demand Breakdown by Type (2018-2028)
Table 21. Current and Estimated Demand Breakdown by Application (2018-2028)
Table 22. Current and Estimated Revenue Breakdown by Type
Table 23. Current and Estimated Revenue Breakdown by Application
Table 24. China Anti-TIGIT Antibody Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 25. Table Current and Estimated Production Breakdown by Type
Table 26. Current and Estimated Demand Breakdown by Type
Table 27. Current and Estimated Demand Breakdown by Application
Table 28. Current and Estimated Revenue Breakdown by Application
Table 29. Japan Anti-TIGIT Antibody Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 30. Current and Estimated Production Breakdown by Type (2018-2028)
Table 31. Current and Estimated Demand Breakdown by Type (2018-2028)
Table 32. Current and Estimated Demand Breakdown by Application (2018-2028)
Table 33. Current and Estimated Revenue Breakdown by Type
Table 34. Current and Estimated Revenue Breakdown by Application
Table 35. India Anti-TIGIT Antibody Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 36. Current and Estimated Production Breakdown by Type (2018-2028)
Table 37. Current and Estimated Demand Breakdown by Type (2018-2028)
Table 38. Current and Estimated Demand Breakdown by Application (2018-2028)
Table 39. Current and Estimated Revenue Breakdown by Type
Table 40. Current and Estimated Revenue Breakdown by Application
Table 41. Korea Anti-TIGIT Antibody Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 42. Current and Estimated Production Breakdown by Type (2018-2028)
Table 43. Current and Estimated Demand Breakdown by Type (2018-2028)
Table 44. Current and Estimated Demand Breakdown by Application (2018-2028)
Table 45. Current and Estimated Revenue Breakdown by Type
Table 46. Current and Estimated Revenue Breakdown by Application
Table 47. Southeast Asia Anti-TIGIT Antibody Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 48. Table Current and Estimated Demand Breakdown by Type (2018-2028)
Table 49. Current and Estimated Demand Breakdown by Application (2018-2028)
Table 50. Current and Estimated Revenue Breakdown by Type
Table 51. Current and Estimated Revenue Breakdown by Application
Table 52. Market Price (USD/Unit) for Each Type of Anti-TIGIT Antibody in US (2018-2022)
Table 53. Market Price (USD/Unit) for Each Type of Anti-TIGIT Antibody in Europe (2018-2022)
Table 54. Market Price (USD/Unit) for Each Type of Anti-TIGIT Antibody in China (2018-2022)
Table 55. Market Price (USD/Unit) for Each Type of Anti-TIGIT Antibody in Japan (2018-2022)
Table 56. Market Price (USD/Unit) for Each Type of Anti-TIGIT Antibody in India (2018-2022)
Table 57. Market Price (USD/Unit) for Each Type of Anti-TIGIT Antibody in Korea (2018-2022)
Table 58. Market Price (USD/Unit) for Each Type of Anti-TIGIT Antibody in Southeast Asia (2018-2022)
Table 59. Key Downstream Customer in Each Application Field
Table 60. Roche Profiles
Table 61. Roche Anti-TIGIT Antibody Product Introduction
Table 62. Roche Anti-TIGIT Antibody Production (Unit), Revenue (Million USD) (2018-2022)
Table 63. Roche Strategic initiatives
Table 64. Merck Profiles
Table 65. Merck Anti-TIGIT Antibody Product Introduction
Table 66. Merck Anti-TIGIT Antibody Production (Unit), Revenue (Million USD) (2018-2022)
Table 67. Merck Strategic initiatives
Table 68. AstraZeneca Profiles
Table 69. AstraZeneca Anti-TIGIT Antibody Product Introduction
Table 70. AstraZeneca Anti-TIGIT Antibody Production (Unit), Revenue (Million USD) (2018-2022)
Table 71. AstraZeneca Strategic initiatives
Table 72. Arcus Profiles
Table 73. Arcus Anti-TIGIT Antibody Product Introduction
Table 74. Arcus Anti-TIGIT Antibody Production (Unit), Revenue (Million USD) (2018-2022)
Table 75. Arcus Strategic initiatives
Table 76. Astellas Profiles
Table 77. Astellas Anti-TIGIT Antibody Product Introduction
Table 78. Astellas Anti-TIGIT Antibody Production (Unit), Revenue (Million USD) (2018-2022)
Table 79. Astellas Strategic initiatives
Table 80. BeiGene Profiles
Table 81. BeiGene Anti-TIGIT Antibody Product Introduction
Table 82. BeiGene Anti-TIGIT Antibody Production (Unit), Revenue (Million USD) (2018-2022)
Table 83. BeiGene Strategic initiatives
Table 84. BMS Profiles
Table 85. BMS Anti-TIGIT Antibody Product Introduction
Table 86. BMS Anti-TIGIT Antibody Production (Unit), Revenue (Million USD) (2018-2022)
Table 87. BMS Strategic initiatives
Table 88. Junshi Biosciences Profiles
Table 89. Junshi Biosciences Anti-TIGIT Antibody Product Introduction
Table 90. Junshi Biosciences Anti-TIGIT Antibody Production (Unit), Revenue (Million USD) (2018-2022)
Table 91. Junshi Biosciences Strategic initiatives
Table 92. Innovent Biologics Profiles
Table 93. Innovent Biologics Anti-TIGIT Antibody Product Introduction
Table 94. Innovent Biologics Anti-TIGIT Antibody Production (Unit), Revenue (Million USD) (2018-2022)
Table 95. Innovent Biologics Strategic initiatives
Table 97. Mereo BioPharma Profiles
Table 98. Mereo BioPharma Anti-TIGIT Antibody Product Introduction
Table 99. Mereo BioPharma Anti-TIGIT Antibody Production (Unit), Revenue (Million USD) (2018-2022)
Table 100. Mereo BioPharma Strategic initiatives
Table 101. Seattle Genetics Profiles
Table 102. Seattle Genetics Anti-TIGIT Antibody Product Introduction
Table 103. Seattle Genetics Anti-TIGIT Antibody Production (Unit), Revenue (Million USD) (2018-2022)
Table 104. Seattle Genetics Strategic initiatives
Table 105. Hengrui Medicine Profiles
Table 106. Hengrui Medicine Anti-TIGIT Antibody Product Introduction
Table 107. Hengrui Medicine Anti-TIGIT Antibody Production (Unit), Revenue (Million USD) (2018-2022)
Table 108. Hengrui Medicine Strategic initiatives
Table 109. Compugen Profiles
Table 110. Compugen Anti-TIGIT Antibody Product Introduction
Table 111. Compugen Anti-TIGIT Antibody Production (Unit), Revenue (Million USD) (2018-2022)
Table 112. Compugen Strategic initiatives